Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia
Authors:
- 19 June 2015
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (2) , 411-418
Abstract
Durable responses to imatinib monotherapy are rarely seen in aggressive forms of Philadelphia chromosome positive (Ph+) leukemias. To investigate the possible cause of treatment failure we examined the role of protein kinase C epsilon (PKCE), an oncogene highly implicated in the development of solid tumors and resistance to chemotherapy. We found high levels of PKCE transcripts in Ph+ acute lymphoblastic leukemia (ALL) cells from patients and cell lines, and imatinib resistant chronic myeloid leukemia, which were also less responsive to imatinib-induced apoptosis than Ph+ cells with lower PKCE expression. Furthermore, the siRNA-mediated knockdown or peptide inhibition of PKCE in Ph+ cells increased imatinib-induced apoptosis while overexpression of PKCE reduced imatinib-induced apoptosis, with concomitant increase in the pro-survival factor AKT. Our results suggest PKCE plays a protective role against apoptosis induced by BCR-ABL inhibition in Ph+ leukemias with high PKCE expression, such as Ph+ ALL.Keywords
This publication has 39 references indexed in Scilit:
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsJournal of Clinical Investigation, 2013
- Insights into the regulation of protein abundance from proteomic and transcriptomic analysesNature Reviews Genetics, 2012
- Role of STAT3 in Transformation and Drug Resistance in CMLFrontiers in Oncology, 2012
- Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilonBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Protein kinase Cɛ mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2)Oncogene, 2010
- Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistanceMolecular Cancer Therapeutics, 2008
- Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN KinaseJNCI: Journal of the National Cancer Institute, 2008
- Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and DasatinibJournal of Biological Chemistry, 2008
- Central Role of Protein Kinase Cε in Constitutive Activation of ERK1/2 and Rac1 in the Malignant Cells of Hairy Cell LeukemiaThe American Journal of Pathology, 2007
- FGF‐2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B‐Raf and S6K2The EMBO Journal, 2006